Navigation Links
Pitt researchers find candidates for new HIV drugs
Date:10/13/2009

PITTSBURGH, Oct. 13 While studying an HIV protein that plays an essential role in AIDS progression, researchers at the University of Pittsburgh School of Medicine have discovered compounds that show promise as novel treatments for the disease.

HIV drug discovery efforts have met with little success in finding compounds that interact with an important HIV virulence factor, called Nef, because it lacks biochemical activity that can be directly measured, explained Thomas E. Smithgall, Ph.D., William S. McEllroy Professor and Chair, Department of Microbiology and Molecular Genetics, and senior author of the paper, which was published last week in the early, online version of ACS Chemical Biology.

To get around that problem, Dr. Smithgall's team developed an assay to measure Nef function indirectly by coupling it to another protein, called Hck, which Nef activates in HIV-infected cells. Because Hck activity can be easily measured, the investigators were able to use it as a reporter for Nef activity in an automated high-throughput screening process. In collaboration with the University of Pittsburgh Drug Discovery Institute, they screened a library of 10,000 chemical compounds against the coupled proteins to see which ones influenced Nef-induced activation of Hck.

After further testing, they confirmed that three compounds inhibited the activity of the Nef-Hck complex and, more importantly, all of them also interfered with HIV replication. One compound was so effective that it suppressed HIV replication to undetectable levels in cell culture experiments.

"So we now have a way to rapidly and efficiently screen for inhibitors of Nef signaling through Hck," Dr. Smithgall said. "But the surprise was that some of those inhibitors also showed strong antiviral activity in cell culture models."

There is evidence that people infected with HIV variants that have mutations in the Nef gene take substantially longer to develop disease symptoms or AIDS, he said. In animal models, disrupting the production of Nef from the virus or its interaction with Hck also delays or prevents disease symptoms. The next challenge for the researchers will be to determine whether these compounds also interfere with progression of AIDS-like disease in animal models by blocking Nef function.

"Most current therapies for HIV infection use drugs that interfere with the function of viral enzymes such as reverse transcriptase or with the interaction of the virus and the host cell," Dr. Smithgall said. "Targeting Nef represents an entirely new approach that could be useful to deal with issues such as drug-resistant HIV strains, and may slow the progression to AIDS."

He added that Nef is just one of several so-called "accessory proteins" encoded by HIV which are important virulence factors in AIDS. Inhibitory compounds against some of the others might be revealed using a similar coupled protein approach for high throughput screening.


'/>"/>

Contact: Anita Srikameswaran
SrikamAV@upmc.edu
412-578-9193
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. Researchers discover mechanism that helps humans see in bright and low light
2. New effort to battle antibiotic resistance rallies researchers throughout Harvard University
3. Researchers report benefits of new standard treatment study for rare pediatric brain cancer
4. Researchers identify genes associated with onset age of Parkinsons disease
5. BUSM researchers identify better laser for treating facial spider veins
6. Toronto researchers discover novel circulation in human eye, new glaucoma treatment target
7. Researchers find demand for cosmetic and surgical procedures in dermatologic surgery rising rapidly
8. Using synthetic evolution to study the brain: Researchers model key part of neurons
9. Researchers at Boston University School of Medicine incorporate multisite geriatric clerkship
10. Researchers use computational models to study fear
11. Researchers develop an integrated treatment for veterans with chronic pain and posttraumatic stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... ... WHO: , Dr. Paul Thomas; Dr. Brian Hooker; Dr. Judy Mikovits; Dr. ... will speak to the press on behalf of over 200 doctors, scientists, and scientific ... commission. , WHERE: , Zenger Room, National Press Club, 529 14th Street NW, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, and the ... results and maintaining GMP and USP compliance. In a new webinar from METTLER ... requirements " these requirements are explained. The challenge is to determine how ...
(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology , a ... time and attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service ... uses biometric face recognition to enable users to check in and out from ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ongoing ... website has recently developed and published an informational resource that addresses frequently asked ... on common inquiries the site’s team of third party administrator (TPA) contributors regularly ...
(Date:3/28/2017)... ... , ... A minimally invasive porcelain veneer is increasing in ... of Dental Laboratories (NADL) is informing dentists about the benefits of minimally invasive ... laboratories and technicians that create these veneers. , According to National Board ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 28, 2017  "US Cancer Generics Market Outlook ... indicators and trend analysis related to the emergence ... pharmaceutical market in US. The report analyzes various ... on cancer generics drugs in recent years. The ... billions of dollars for various stake holders involved ...
(Date:3/28/2017)... 29, 2017 Center Point Clinical ... platform, announced today study results presented in two ... #AMCP2017, Managed Care and Specialty Pharmacy annual meeting ... in both posters demonstrated that pharmacist-led patient interventions during ... These factors are crucial to generating the robust and ...
(Date:3/28/2017)... 28, 2017 This morning,s ... four stocks: The Medicines Co. (NASDAQ: MDCO), Ironwood ... PCRX), and Supernus Pharmaceuticals Inc. (NASDAQ: ... Drugs space which is governed by the same ... for the industry are wholesalers, retailers, pharmacies, and ...
Breaking Medicine Technology: